Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of Biotinylation Protocol for RBC Survival
NCT06788080Phase 1Completed
- Sponsor
- Vitalant Research Institute
- Start
- Mar 2024
- Primary completion
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Biotinylated red blood cell, sponsored by Vitalant Research Institute. Primary endpoint: Percent BioRBC recovery at 24 hours. Started Mar 2024; status: completed.
02
Drugs
Biotinylated red blood cell
Beyond the preview
Go deeper on NCT06788080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06788080.